Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

Theo M. de Witte, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen, Eva Hellstrom-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Jan Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1754-1761
JournalHaematologica-the Hematology Journal
Volume95
Issue number10
DOIs
Publication statusPublished - Oct 2010

Keywords

  • myelodysplastic syndromes
  • secondary acute myeloid leukemia
  • cytogenetic characteristics
  • allogeneic stem cell transplantation
  • autologous stem cell transplantation
  • intensive chemotherapy

Cite this

de Witte, T. M., Hagemeijer, A., Suciu, S., Belhabri, A., Delforge, M., Kobbe, G., Selleslag, D., Schouten, H. C., Ferrant, A., Biersack, H., Amadori, S., Muus, P., Jansen, J. H., Hellstrom-Lindberg, E., Kovacsovics, T., Wijermans, P., Ossenkoppele, G. J., Gratwohl, A., Marie, J-P., & Willemze, R. (2010). Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica-the Hematology Journal, 95(10), 1754-1761. https://doi.org/10.3324/haematol.2009.019182